Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Revenue (2018 - 2025)

Cue Biopharma (CUE) has disclosed Revenue for 8 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 502.79% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, up 61.77% year-over-year, with the annual reading at $27.5 million for FY2025, 195.75% up from the prior year.
  • Revenue hit $9.5 million in Q4 2025 for Cue Biopharma, up from $2.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.5 million in Q4 2025 to a low of $26000.0 in Q2 2022.
  • Historically, Revenue has averaged $2.3 million across 5 years, with a median of $1.8 million in 2023.
  • Biggest five-year swings in Revenue: tumbled 99.05% in 2022 and later skyrocketed 5215.38% in 2023.
  • Year by year, Revenue stood at $8.3 million in 2021, then tumbled by 98.17% to $151000.0 in 2022, then skyrocketed by 1105.96% to $1.8 million in 2023, then fell by 13.45% to $1.6 million in 2024, then skyrocketed by 502.79% to $9.5 million in 2025.
  • Business Quant data shows Revenue for CUE at $9.5 million in Q4 2025, $2.1 million in Q3 2025, and $3.0 million in Q2 2025.